News

Article

How Circulating Tumor Cell Count Can Inform Prostate Cancer Treatment

Author(s):

Fact checked by:

Key Takeaways

  • Elevated baseline CTC counts are linked to worse overall survival, progression-free survival, and treatment response in cancer patients.
  • In prostate cancer, patients with five or more CTCs at treatment start had significantly shorter median survival compared to those with no detectable CTCs.
SHOW MORE

An expert explained how circulating tumor cell count can identify possible clinical trial participants.

Circulating tumor cell (CTC) count can help inform treatment decisions for patients with cancer, including which patients are the most appropriate potential clinical trial participants, as an expert explained in an interview with CURE®.

Circulating tumor cells are material shed from tumors into the bloodstream, and they can be measured with a blood draw known as a liquid biopsy.

Researchers, who published their findings in JAMA Network Open, have found that elevated CTC count at baseline is associated with statistically significantly worse overall survival (OS), progression-free survival (PFS) and treatment response.

Study co-author Dr. Amir Goldkorn of the Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, spoke with CURE® about the findings and how they could inform patient treatment decisions.

Glossary:

Overall survival (OS): how long a patient lives, regardless of disease status.

Progression-free survival (PFS): the time a patient lives without their disease spreading or worsening.

Transcript:

What we found was that one baseline test, right at the start of when they began hormonal therapies and everything else, was able to predict how well patients were going to respond to the treatment, how long they would be responding to the treatment and how long overall they would be living with immediate overall survival with various treatments for prostate cancer. So for example, and sort of the big take-home for overall survival, was that men who had five or more CTCs in their blood at the start of treatment only lived, on average, about two and a half years, like 29 months, whereas men who had no detectable CTCs in their blood at the start of treatment, their median survival hadn't even been reached out to like 78 months, like six and a half years. We're still waiting for their average survival to hit. So they were living much, much longer.

And this is despite the fact that all these men went on to have hormonal therapies, and then they maybe progressed and went on to other treatments and chemo and this and that, you go on multiple lines of therapy for years, and yet, regardless of all that downstream stuff, that first baseline test was able to tell us, ultimately, who was going to have a shorter expected life with their cancer and who was going to survive much longer.

And the impact of that is that as we constantly strive to develop newer treatments and new combinations that may be more toxic but also more aggressive and maybe help control the cancer, we test those in clinical trials, we want to know who should be put on those trials, right? I mean, we want to ideally offer those trials to men who have very aggressive disease or are not expected to live very long with the treatments we now have. So this could be used as a test where men come in through the door, they have their CTC counts tested and say they have zero CTCs, maybe they get sort of the usual kind of standard therapies, they're going to be doing quite well with them for a long time. But if they have, say, five or 10 or 15 CTCs in the blood, we say, 'Well, OK, you're not expected to live, unfortunately, very long. This is an aggressive disease. It's going to progress quickly. You're going to not have as long a lifespan,' maybe we offer that kind of patient the newer trials with more intensified therapies or novel combinations, things like that.

Transcript has been edited for clarity and conciseness.

Reference:

“Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer” by Dr. Amir Goldkorn et al., JAMA Network Open.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Related Content